Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.

Blood advances·2023
Same author

Plamotamab (XmAb<sup>®</sup>13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia.

Leukemia & lymphoma·2021
Same author

Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma.

Oncotarget·2021
Same author

An open-label study evaluating the efficacy of abatacept in alopecia areata.

Journal of the American Academy of Dermatology·2020
Same author

High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata.

JCI insight·2018
Same author

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.

Breast cancer research : BCR·2018

Related Experiment Video

Updated: Jul 17, 2026

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

IVIG therapy: interfering with interferon-gamma.

Raphael Clynes1

  • 1Department of Medicine and Microbiology, Columbia University, New York, NY 10032, USA. rc645@columbia.edu

Immunity
|January 24, 2007
PubMed
Summary

Intravenous immune globulin (IVIG) treats autoimmunity by engaging Fcgamma RIII receptors on monocytes. This interaction suppresses the cellular response to interferon-gamma, revealing a key immunosuppressive mechanism.

Area of Science:

  • Immunology
  • Autoimmunity
  • Cellular Biology

Background:

  • Intravenous immune globulin (IVIG) is widely used for autoimmune diseases.
  • The precise immunosuppressive mechanisms of IVIG remain incompletely understood.
  • Previous research has not fully elucidated how IVIG modulates immune cell responses.

Discussion:

  • This study identifies a novel mechanism for IVIG's immunosuppressive effects.
  • IVIG binding to Fcgamma RIII receptors on monocytes is a critical step.
  • The inhibition of interferon-gamma signaling is a direct consequence of IVIG engagement.

Key Insights:

  • IVIG directly inhibits monocyte responses to interferon-gamma.
  • Fcgamma RIII receptor engagement by IVIG is essential for this effect.

More Related Videos

Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production
08:32

Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production

Published on: March 2, 2014

Related Experiment Videos

Last Updated: Jul 17, 2026

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production
08:32

Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production

Published on: March 2, 2014

  • This finding provides a molecular basis for IVIG's therapeutic action in autoimmunity.

    • Outlook:

    • Further research can explore targeting this pathway for enhanced autoimmune therapies.
    • Understanding this mechanism may lead to more specific immunomodulatory treatments.
    • Clinical applications could benefit from this detailed mechanistic insight.